Rexahn Pharmaceuticals (NYSEMKT:RNN)

zzlangerhans (99.78) Submitted: 8/7/2012 5:28:21 AM : Start Price: $0.51 RNN Score: +8.83

I'm dropping a red thumb on a 50 cent stock for a change since I think the company will be reporting negative data from their phase II trial of Archexin in pancreatic cancer in the near future. That will likely be followed by a reverse split and a capital raise, if I read the tea leaves correctly.

And now a dose of accountability, rarely seen in the small cap community:

ME Garza. May 6, 2011. http://seekingalpha.com/article/268349-rexahn-pharma-reports-two-thirds-of-patients-enrolled-in-key-clinical-trial Share price 1.16

Jeremy Williams. May 31, 2011. http://seekingalpha.com/article/272515-rexahn-is-a-bargain-buy Share price 1.31

Thanks, Seeking Alpha, for sharing the insights of these two titans of biotech analysis.